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a b s t r a c t
Cardiac implantable electronic devices (CIEDs) have become important in the treatment of cardiac
disease and placement rates increased signiﬁcantly in the last decade. However, despite the use of
appropriate antimicrobial prophylaxis, CIED infection rates are increasing disproportionately to the
implantation rate. CIED infection often requires explantation of all hardware, and at times results in
death. Surgical site infection (SSI) is the most common cause of CIED infection as a pocket infection. The
best method of combating CIED infection is prevention. Prevention of CIED infections comprises three
phases: before, during, and after device implantation. The most critical factors in the prevention of SSIs
are detailed operative techniques including the practice of proper technique by the surgeon and
surgical team.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Background
The development of transvenous electrodes and downsized
generators over the past two decades has permitted physicians to
place cardiac implantable electronic devices (CIEDs), and even high
voltage devices such as implantable cardioverter-deﬁbrillators or
cardiac resynchronization therapy devices with a deﬁbrillator, using
techniques similar to those employed for permanent pacemaker
insertion [1–5]. As a result, CIED implantation rates have increased
signiﬁcantly in the last decade and these devices gained importance
in the treatment of cardiac disease for their ability to reduce
morbidity and mortality in selected patients [6,7]. CIED implanta-
tion by a cardiologist in an electrophysiology laboratory has several
advantages including support by specialized staff and the avail-
ability of appropriate monitoring and radiological equipment.
However, these beneﬁcial procedures are associated with risks,
including infection.
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Infection is the most serious complication of CIED implantation
and requires explantation of all hardware, with fatalities occurring
in 3–19% of patients [8]. CIED infections are associated with
signiﬁcant morbidity, mortality, and cost [9–11]. Infection rates
associated with device implantation are reported to be between
1% and 7% [12]. The majority of CIED infections are caused by
staphylococcal species, which account for 60–80% of cases in most
reported series [13–15]. Coagulase-negative staphylococcal spe-
cies, often S. epidermidis, are the most common pathogens (42%)
reported to cause CIED infections [16]. Staphylococcus aureus is the
second most common pathogen (25%).
The current American Heart Association (AHA)/Heart Rhythm
Society (HRS) recommendation for prophylaxis at the time of CIED
placement is an antibiotic that possesses in vitro activity against
staphylococci [9]. Recent large studies indicate that the vast
majority of patients receive antimicrobial prophylaxis with CIED
placement [17,18]. However, despite the widespread use of appro-
priate antimicrobial prophylaxis, CIED infection rates are increas-
ing disproportionately to implantation rates [19].
2. Surgical site infection
The Centers for Disease Control and Prevention (CDC) has
developed criteria for deﬁning surgical site infection (SSI) [20],
which replaced the previous term ‘surgical wound infection’. This
guideline became the worldwide standard and is widely used for
surveillance, including in Japan (i.e., Japan Nosocomial Infections
Surveillance; JANIS). These criteria deﬁne SSIs as infections related
to the operative procedure that occur at or near the surgical
incision (incisional or organ/space) within 30 days of an operative
procedure or within 1 year if an implant is left in place. Incisional
SSIs are further divided into those involving only the skin and
subcutaneous tissue (superﬁcial incisional SSIs) and those invol-
ving deeper soft tissues (deep incisional SSIs). Organ/space SSIs
involve any part of the anatomy (e.g., organ or space), other than
the incised body wall layers, that was opened or manipulated
during an operation. These deﬁnitions should be universally
followed for the surveillance, prevention, and control of SSIs.
Along with this guideline, cardiac device infections can also be
deﬁned and classiﬁed as ‘pocket infections’ and ‘deeper infections’.
The term ‘pocket infection’ is used when the infection involves the
subcutaneous pocket containing the device and the subcutaneous
part of the leads. The term ‘deeper infection’ is used when the
infection involves the transvenous portion of the lead, usually in
association with bacteremia and/or endovascular infection. Alter-
natively, device infections may be classiﬁed by the mode of
infection. Primary infections, in which the device and/or pocket
itself is the source of infection, are usually due to contamination at
the time of implantation. A secondary infection occurs when the
leads (and sometimes the device and pocket) are seeded by
bacteremia from a different source (i.e., hemodialysis vascular
access or dental abscesses).
3. Prevention of CIED infection
The prevention of CIED infections comprises three phases:
before, during, and after device implantation. The most critical
factors in the prevention of SSIs are detailed operative techniques
including the practice of proper technique by the surgeon and
surgical team. Table 1 shows interventions that have been used to
reduce the risk of SSIs [20]. Most interventions were developed to
reduce contact with normal microbial ﬂora from hospital person-
nel, believed to be the source of microorganisms causing SSIs.
3.1. Preoperative prevention
Fever elevation within 24 h before implantation is associated
with the development of CIED infection [17]. Therefore, patients
should be screened for evidence of infection prior to implantation.
All remote infections should be adequately treated before elective
operations, and implantation should be postponed until the
infection has resolved. If urgent surgery is required, the risk of
infection must be weighed against the timing of surgical inter-
vention on an individual basis.
3.1.1. Hair removal and skin sterilization (anti-sepsis)
In the past, hair removal was commonly performed before
most surgical procedures to provide a clean operative ﬁeld and
prevent bacteria in hair follicles from entering the surgical site.
However, most studies have found an increased risk of SSIs in
patients undergoing preoperative hair removal [21]. Therefore, it is
not recommended to remove hair perioperatively unless the hair
at or around the incision site will interfere with the operation [20].
The CDC also recommends that patients be required to shower
or bathe with an antiseptic agent at least on the night before
surgery [20]. However, the beneﬁt of bathing with an antiseptic
preparation prior to surgery to reduce the risk of SSIs has been
questioned. In a meta-analysis of six trials involving 10,007
participants, preoperative bathing with chlorhexidine conferred
no beneﬁt in terms of SSI reduction over preoperative bathing
with other products such as non-antiseptic washing agents [22].
The CDC also recommends thoroughly washing and cleaning at
and around the incision site to remove contamination before
performing an antiseptic skin preparation. The application of
antiseptics to the skin immediately prior to surgery is a routine
practice in almost all operations, and perioperative antiseptic
preparation of the skin of the surgical site should be performed
with an approved antiseptic agent. The antiseptic should be
applied over the incision site in concentric circles starting from
the incision site and moving toward the periphery.
3.1.2. Antibiotic prophylaxis
In a clean operation such as cardiovascular or brain surgery, the
incidence of SSIs is relatively low. However, once it occurs, it
becomes increasingly severe. Therefore, systemic prophylactic
antibiotics at the time of CIED implantation are recommended.
At present, there are no guidelines on systemic prophylactic
antibiotic use in CIED implantation and no trials comparing
systemic prophylactic antibiotic regimens. Data from some studies
[17,23–25] support the administration of antibiotic prophylaxis for
CIED implantation. The CDC recommends that vancomycin should
not be used routinely for antimicrobial prophylaxis because of the
risk of postoperative methicillin-resistant S. aureus infection [20].
In a clean operation, cefazolin, which is effective for skin ﬂora, is
usually used for prophylaxis.
Table 1
Interventions that have been used to reduce the risk of SSIs.
✓ Preoperative showering with antimicrobial soapsa
✓ Preoperative application of antiseptics to the skin of the patient
✓ Washing and gloving of the surgeon's hands
✓ Use of sterile drapes
✓ Use of gowns and masks by operating room personnel
a Not available in Japan
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3.1.3. Preoperative disease and status control (including smoking
cessation)
Several preoperative host factors associated with a greater risk
of CIED infection were described previously (Table 2) [9,17]. When
possible, these risks should be mitigated. The CDC recommends
that serum blood glucose levels be adequately controlled in all
diabetic patients and in particular, that preoperative hyperglyce-
mia be avoided. The CDC also recommends instructing patients to
abstain from smoking cigarettes, cigars, or pipes and avoid any
other form of tobacco consumption (e.g., chewing/dipping) for at
least 30 days (at minimum) before elective surgery [20].
3.2. Intraoperative prevention
The most important factors for the prevention of SSIs are
detailed operative techniques including the practice of proper
technique by the surgeon. Before starting the surgery, operating
room personnel should be equipped with barrier devices (masks,
caps, gowns, drapes, and shoe covers) as protection against
exposure to infectious blood or body ﬂuids. Prior to surgery,
physicians should perform a surgical scrub including the hands
and forearms for at least 2–5 min with an appropriate antiseptic
agent. This is an accepted practice, and guidelines support using
either an antimicrobial soap or an alcohol-based hand rub with
persistent activity for surgical hand antisepsis [26]. Cleaning
underneath each ﬁngernail prior to performing the ﬁrst surgical
scrub of the day is recommended. After performing the surgical
scrub, physicians should keep their hands up and away from their
body. Hands should be dried with a sterile towel before donning a
sterile gown and gloves.
3.2.1. General surgical technique
There is general agreement that good surgical technique
reduces the risk of SSIs (Table 3) [27]. However, the role of these
techniques in SSI prevention in relation to CIEDs is not supported
by strict study. Intraoperatively, compulsive or obsessive attention
to sterile technique is mandatory. Usually, CIEDs can be implanted
in pockets fashioned in the prepectoral subcutaneous space.
However, in lean or small subjects, especially in Japanese people,
who are thought to be at risk of pocket erosion, the formation of
deep pockets beneath the major pectoral muscle has been recom-
mended [28–30]. Because such pockets require deep dissection,
traumatic injury to the small vessels or nerve system, accidental
bleeding, or postoperative hematoma can occur. To minimize such
traumatic pocket complications, prepectoral subfascial implanta-
tion has been employed since the early 1990s mainly for large
devices (Fig. 1) [31,32], although limited data support this practice.
In any and all circumstances, hematoma formation should be
avoided by meticulous cautery of bleeding sites since hematoma
involving a pocket has been identiﬁed as a risk factor in device
placement [33]. Therefore, hematoma prevention during the
procedure is desirable. Frequent irrigation of the pocket is useful
for removing tissue debris and may reveal persistent bleeding that
could lead to a pocket hematoma. The effectiveness of prophylactic
intrapocket antibiotics in CIED implantation has not been evalu-
ated in randomized controlled trials. The presence of antibiotics in
irrigation solutions is unlikely to be necessary. Rather, the
mechanical action of debris removal and dilution of any contami-
nant are due to the ﬂow and volume of irrigation. The use of
monoﬁlament sutures for closure of the subcuticular layer may
prevent superﬁcial postoperative cellulitis. A pressure dressing
applied postoperatively for 12–24 h after skin closure may help
prevent infection and further decrease the risk of hematoma
formation.
3.3. Postoperative prevention
In cases of hematoma formation, it is recommended that the
hematoma only be evacuated in the presence of increased skin
tension, suggesting a risk of dehiscence. In general, needle aspira-
tion should be avoided because of the risk of introducing skin ﬂora
into the pocket, which may subsequently develop into infection.
Prolonged pressure dressing (43 days) of the pocket can help
prevent hematoma formation even if anticoagulation or anti-
platelet agents were administered. Recent AHA guidelines recom-
mend early follow-up in a clinic setting as well as thorough patient
education to achieve early identiﬁcation of CIED-related infectious
complications [9].
Postoperative prophylactic systemic antibiotics are commonly
used, although there is wide variation in the duration of treat-
ment. One study that investigated the duration of postoperative
Table 3
Good surgical technique reducing the risk of SSIs.
✓ Gentle traction
✓ Effective and obsessive hemostasis
✓ Removal of devitalized tissues
✓ Obliteration of dead space
✓ Enough irrigation of tissues with saline
✓ Use of non-absorbed monoﬁlament suture material
✓ No or judicious use of closed suction drains
✓ Wound closure without tension
Modiﬁed from Altemeier et al. [27], 54.
Fig. 1. To minimize traumatic pocket complications such as hematoma formation,
prepectoral subfascial implantation has been employed. By chipping off the entire
muscle body, using the ﬁngers to gently spread the tissues apart slightly medially
and caudally, the pocket is formed simply by the reduced adhesion between the
fascia and muscle.
Table 2
Patients background risk factors associated with CIED infection.
✓ Advanced patient age
✓ Congestive heart failure
✓ Diabetes mellitus
✓ Immunosuppression (corticosteroid use)
✓ Oral anticoagulation use
✓ Patient coexisting illnesses
✓ Failure to administer perioperative antimicrobial prophylaxis
✓ Preprocedural temporary pacing
✓ Renal dysfunction
✓ The amount of indwelling hardware (leads)
✓ The microbiology of bloodstream infection
✓ Underlying malignancy
✓ Current smoke
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antibiotics compared short-term (2 days) with longer-term (7
days) use [34]. This study suggested that a short course is just as
effective as a longer course in preventing CIED infections. Cur-
rently, there is insufﬁcient evidence to support the administration
of postoperative antibiotic therapy, and the use of postimplanta-
tion antibiotics is not recommended in the recently updated AHA
guidelines [9]. There is currently no scientiﬁc basis for the use of
prophylactic antibiotics before routine dental, gastrointestinal, or
genitourinary procedures to prevent CIED infections.
4. Conclusions
Infection is the most serious complication of CIED implantation.
Once it develops, it often requires explantation of all hardware
with strong invasion and sometimes results in death. The best
method of combating CIED infection is prevention. The most
critical factors in the prevention of CIED infection are detailed
operative techniques including the practice of proper technique by
the surgeon and surgical team. Improved antimicrobial prophy-
laxis is one approach to reducing the morbidity, mortality, and
expense associated with infection after CIED implantation.
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